Literature DB >> 31344705

Cervical Cancer with Intermediate Risk Factors: Is there a Role for Adjuvant Radiotherapy? A Systematic Review and a Meta-Analysis.

Lena Sagi-Dain1, Sereen Abol-Fol1, Ofer Lavie1,2, Shlomi Sagi3, Alon Ben Arie4, Yakir Segev5,6.   

Abstract

BACKGROUND: The yield of adjuvant radiotherapy in cervical cancer patients with intermediate risk factors is controversial. The objective of our meta-analysis was to shed light on this important issue.
MATERIAL AND METHODS: Search was conducted in several databases. By independent screening of titles and abstracts, 2 investigators selected original researches examining the effect of adjuvant radiation treatment on overall survival and progression-free survival in cervical cancer patients with intermediate risk factors.
RESULTS: Of the 5 articles included, a total of 591 patients with intermediate risk factors were encompassed. Statistical significance was noted in favor of radiation therapy in a subgroup of patients with 2 or more intermediate factors in terms of recurrence (OR 0.46 [95% CI 0.28-0.74, p = 0.001]) and overall survival (OR 1.86 [95% CI 1.03-3.36, p = 0.04]). After adding patients with one risk factor, radiation exerted a non-significant effect on recurrence rate, overall survival, disease-free survival, and 5-year cancer-specific survival, while increasing the rate of gastrointestinal side effects (2.4 vs. 0%, p = 0.0156).
CONCLUSIONS: Adjuvant radiation therapy decreases the risk for recurrence and increases the overall survival in patients with 2 intermediate risk factors. These benefits were not shown after adding patients with one risk factor.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Adjuvant radiation; Cervical cancer; Intermediate risk factor

Year:  2019        PMID: 31344705     DOI: 10.1159/000501683

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

1.  Targeting survivin sensitizes cervical cancer cells to radiation treatment.

Authors:  Jing Zhou; Xiaojing Guo; Weifen Chen; Liming Wang; Yonglong Jin
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.